The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $799,107 Project Grant to the Dana-Farber Cancer Institute, Inc. in Boston, MA to conduct research on using genomic biomarkers and decision analysis frameworks to guide treatment decisions for stage III melanoma patients. The grant will fund a collaborative project involving researchers from Dana-Farber and Brigham & Women's Hospital to develop methods for translating genomic and histological data into predictive models to improve the efficacy and reduce the toxicity of immune checkpoint blockade therapies for melanoma patients. The sub-award to Brigham & Women's Hospital will provide dermatopathological expertise to integrate histological features with the genomic analysis. The project aims to advance precision oncology approaches to melanoma treatment through data-driven, biomarker-informed decision analytics.
Generated 1/28/25, 10:27 AM